Further studies are needed to determine if SIK inhibitors increase 1,25-vitamin D levels of other CKD models with interstitial fibrosis and to assess the effect of long-term SIK inhibitor treatment on clinically relevant CKD-MBD endpoints, such as vascular calcification and renal osteodystrophy. The gene discussed is SIK1; the disease is Marchiafava-Bignami disease.